01 — Evidence
Evidence Summary
Modified citrus pectin has a single, well-defined mechanism — antagonising galectin-3 — and the evidence for it is strongest in animals and weakest, or absent, exactly where it matters most: controlled human tumor outcomes. The three tiers below are read together because the gap between them is the whole story: a reproducible anti-metastatic mechanism, a suggestive but uncontrolled human biomarker signal, and an unresolved question of whether an oral dose reaches the target.
Human
Clinical Record
Uncontrolled — biomarker signal, no shrinkage
The human record is small and uncontrolled. Its main strand is prostate cancer measured by PSA doubling time — a progression-tempo biomarker, not tumor shrinkage: across a 2003 pilot and a later manufacturer-funded phase II cohort followed to 18 months, a majority showed a lengthened doubling time, with good tolerability. A separate older pilot in advanced mixed solid tumors looked directly for tumor response and found mostly stable or progressive disease, with no shrinkage. No human data support the older claims of lowered blood galectin-3 or improved counts under chemotherapy.
Animal
Preclinical Signal
Anti-metastatic, oral — but now conflicting
Older oral-dosing studies are where the case lives, targeting the galectin-3-dependent adhesion and seeding steps — but a 2026 study now conflicts with them, making the in-vivo picture mixed rather than settled.
- Reduced spontaneous lung metastasis in a rat prostate model
- Reduced growth, angiogenesis, and metastasis in carcinoma xenografts
- Lowered colon-to-liver metastasis and cut melanoma lung colonization
- But a 2026 study found no oral absorption and no oral antitumor effect
In Vitro
Cell Model Data
Anti-adhesion clear; cell-killing contested
At the cell level MCP has reliably been reported to do one thing — interfere with galectin-3-dependent adhesion, aggregation, and migration. Its direct cell-killing is another matter, and genuinely disputed.
- Inhibited homotypic aggregation and adhesion to laminin
- Suppressed migration of breast and prostate cancer cells
- Apoptosis is contested — one study found MCP had little or none
- Active concentrations far exceed plausible oral exposure
Human
Clinical Record
There is no controlled human evidence that oral MCP shrinks a tumor or extends survival. The human record has two uncontrolled strands. The larger is prostate cancer measured by PSA doubling time — a progression-tempo biomarker, not a tumor-response measure, and every study is single-arm. Within those limits the direction is consistent: a phase II pilot reported a lengthened PSA doubling time in 7 of 10 evaluable men after 12 months of oral MCP,[1] and a later prospective phase II study (59 treated over 6 months) reported doubling-time improvement in about three-quarters of participants with a significant median increase.[2]
Continue reading — full research detail+
The 18-month figures come from an extension of that same cohort, not a new study: only the patients who had not progressed at six months were eligible to continue — a responder-enriched subset — and among the 39 who entered it, 85% had a durable response and 90% a doubling-time improvement.[3] Because the extension pre-selected non-progressors, its high response rates describe a survivor subset rather than independent replication. Tolerability was good across the studies, with no high-grade toxicity. Both prospective-cohort reports were funded by the maker of the studied PectaSol product, and a co-author disclosed being its developer — which does not invalidate the uncontrolled findings but raises the importance of independent, controlled replication. The trials did track radiologic progression as a secondary endpoint, and a minority of patients progressed radiologically; what the record lacks is any randomized comparison, or controlled evidence that MCP improves radiographic progression, metastasis-free survival, or overall survival. The second strand is a single older pilot that looked directly for tumor response: 49 patients with various advanced solid tumors received 15 g/day MCP, and of the 26 evaluable, 11 had stable disease and 15 progressed by 8 weeks, with 6 stable beyond 24 weeks and no objective shrinkage.[29] It is heterogeneous, high-attrition, and uncontrolled — hypothesis-neutral at best — but it means the human record includes a RECIST tumor-response readout, not PSA kinetics alone. Despite the mechanism, no human study shows MCP lowers circulating galectin-3, improves blood counts during chemotherapy, or affects colorectal cancer specifically.
Signal maturity: the human evidence is a directionally consistent progression-tempo signal in a single cancer and a single biomarker, from uncontrolled and largely manufacturer-funded studies — and uncontrolled PSA-doubling-time measures can lengthen even when an intervention is inert. It should be read as hypothesis-generating: it establishes that a controlled trial is warranted, not that MCP changes the course of disease.
Animal
Preclinical Signal
The tumor-directed case for MCP is carried by animal models, and in the older studies it is reproduced across tumor types and, unusually, produced by oral dosing. In a rat Dunning MAT-LyLu prostate model, oral MCP cut spontaneous lung metastases from 9±4 to 1±1 colonies at the top dose without touching the primary tumor,[4] and in nude mice oral MCP reduced growth, angiogenesis, and spontaneous metastasis of a human colon carcinoma (LSLiM6) and a second orthotopic line, MDA-MB-435 — long used as a breast-carcinoma model but later identified as melanoma-derived, so its result counts as carcinoma-model rather than clean breast evidence.[5] The effect spans further tumor types: reduced colon-to-liver metastasis in a CT26 model (incidence 100% down to 60%),[6] and a greater-than-90% cut in experimental melanoma lung colonization — where unmodified pectin instead increased it.[7]
Continue reading — full research detail+
Two findings extend the picture beyond metastasis. In bladder cancer, oral MCP significantly inhibited the growth of a primary xenograft, lowering the proliferation marker Ki67 and raising apoptosis, through downregulation of galectin-3 and its downstream Akt signaling[9] — a direct oral effect on a primary tumor, and the clearest counterpoint to the pharmacokinetic doubt raised below. Mechanistically, an elegant in-vivo study showed that metastatic arrest depends on intercellular (galectin-3-mediated) adhesion rather than mechanical trapping, and that combining MCP with adhesion blockade cut lung and bone deposit formation by more than 90%.[8] A separate, newer thread reports MCP improving how chemotherapy performs — restoring drug sensitivity and easing a chemotherapy toxicity — detailed under Protect below.[25,26]
Signal maturity: the older animal evidence is the most substantial part of MCP's profile — multi-cancer, oral, and mechanistically consistent with galectin-3 antagonism — but it is no longer uncontested: a 2026 radiolabeled study found negligible oral absorption and no oral antitumor effect in its models,[23] making the oral in-vivo case conflicting rather than settled. These are also administered doses in animals whose systemic exposure is itself uncertain, and no animal result substitutes for a controlled human outcome.
In Vitro
Cell Model Data
At the cell level MCP has been reported to do one thing reliably and another thing contentiously. Reliably, it interfered with the galectin-3-dependent physical steps of metastasis: it inhibited asialofetuin-induced homotypic aggregation and adhesion to laminin in melanoma cells,[10] and dose-dependently suppressed the migration of human breast and prostate cancer cells.[11] Contentiously, its ability to directly kill cancer cells is disputed: PectaSol-C induced apoptosis and inhibited MAPK signaling in prostate cell lines,[12] yet a structural study found citrus pectin and pH-modified PectaSol had "little or no apoptotic activity" where a differently fractionated pectin was strongly pro-apoptotic.[14]
Continue reading — full research detail+
MCP also showed an immune signal in cell culture — it activated human natural killer cells that then killed K562 leukemia cells — but this was ex-vivo blood-cell work, not a tumor-bearing model.[13] The load-bearing caveat over all of it is exposure: the concentrations that drive these effects in a dish are far higher than a large polysaccharide could plausibly reach in plasma after oral dosing, so the cell data describe what MCP can do at the target, not what an oral dose delivers. Much of the broader galectin-3 pathway map — inflammatory, proliferative, and immune nodes — was established with galectin-3 knockdown or with other galectin-3 inhibitors, and is carried below as mechanistic context rather than demonstrated MCP action.
Signal maturity: in-vitro evidence firmly supports an anti-adhesion, anti-migration mechanism and genuinely disputes a direct cell-killing one. Read every cell-level effect through the Pharmacokinetics and Administration section below, where the exposure question is unresolved.
Advertisement
02 — Pathways
Pathway Interaction Profile
MCP's dominant proposed target is galectin-3, so most of its cited pathways cluster around one theme: containing the spread of disease by blocking the adhesion, niche-formation, and invasion steps galectin-3 supports (though not every reported MCP effect is galectin-3-mediated). Each role below is classified partial: the mechanisms are real and, for Contain and Weaken, corroborated in living animals, but the oral exposure a person achieves is unproven and, in one direct measurement, negligible.
MCP's Contain classification is its core role and rests on in-vivo evidence: reduced adhesion, angiogenesis, and metastasis have been confirmed in living tumors across more than one cancer type, all traceable to galectin-3 antagonism. It is read as partial because those effects were produced by administered animal doses whose systemic exposure is uncertain, and because the one direct pharmacokinetic measurement found negligible oral uptake.
Prevent Arrest & Adhesion
Research concerning endothelial adhesion and platelet-mediated arrest at secondary sites.
Integrin–FAK–Src signaling (focal adhesion)
Galectin-3 mediates tumor-cell arrest by anchoring circulating cells to endothelium; endothelial integrin α3β1 then stabilizes that adhesion and assembles a focal-adhesion complex activating Src, p38, and ERK1/2.[15] MCP is the anti-adhesion counter — it inhibited homotypic aggregation and laminin adhesion in melanoma cells,[10] and combined with adhesion blockade it cut in-vivo metastatic-deposit formation by more than 90% in a model showing that intercellular adhesion, not mechanical trapping, governs arrest.[8] The most MCP-specific, load-bearing Contain node.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
Angiogenesis / VEGF / HIF-1α
Oral MCP reduced tumor angiogenesis alongside spontaneous metastasis in vivo,[5] consistent with galectin-3's pro-angiogenic role: MMP-cleaved galectin-3 drives endothelial migration, invasion, tube formation, and focal-adhesion-kinase phosphorylation, raising microvessel density.[16] The VEGFR2-retention and HIF-1α links for MCP specifically are reported in review synthesis rather than a primary MCP assay.[22]
NF-κB / TNF-α / IL-6 inflammatory axis
In orthotopic breast models, hypoxia raised galectin-3 secretion by tumor-associated macrophages, driving reactive-oxygen-species-dependent NF-κB activation and metastasis; MCP blocked this axis, with stronger inhibition when combined with the anti-angiogenic drugs sorafenib or bevacizumab.[17] One of the few pathway demonstrations using MCP itself in vivo.
Prevent Tumor Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
MCP has been reported to reduce galectin-3-mediated tumor–laminin and extracellular-matrix interactions and matrigel invasion, and to reverse epithelial–mesenchymal transition,[22] consistent with its dose-dependent inhibition of breast and prostate cancer-cell migration[11] and the reduced spontaneous metastasis seen across the in-vivo models.[5]
MCP's Weaken classification is narrow but MCP-specific: by lowering galectin-3, it is reported to dampen the survival signaling that keeps tumor cells proliferating. It is read as partial because it rests on a single oral in-vivo study plus in-vitro corroboration, and is subject to the same unresolved question of oral exposure.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
PI3K–AKT–mTOR (signaling)
In bladder cancer, MCP downregulated galectin-3 and inactivated Akt signaling, producing G2/M cell-cycle arrest with lower Cyclin B1 and phospho-Cdc2; oral MCP significantly reduced primary xenograft growth and Ki67 in vivo, an effect reproduced by galectin-3 knockdown.[9] The load-bearing Weaken node, and demonstrated with MCP itself in a living tumor.
RAS–RAF–MEK–ERK (MAPK)
Both PectaSol and PectaSol-C inhibited MAPK activation and raised the pro-apoptotic protein Bim in androgen-dependent and -independent prostate cancer cells, with caspase-3 cleavage — an MCP-specific proliferative-signaling effect, though shown in vitro and at a concentration well above plausible systemic exposure.[12]
MCP's Protect classification is preclinical and supportive-care-shaped: it rests on animal evidence that MCP improves how chemotherapy performs and is tolerated, not on host-outcome human trials, so it carries a cited Oncology Host-Status summary rather than pathway cards. It is read as partial because the host benefit is real and MCP-specific but demonstrated only in animals.
Oncology Host-Status
Chemotherapy-combination (chemosensitization) — preclinical — oral MCP restored gemcitabine sensitivity in orthotopic pancreatic-cancer xenografts by reversing galectin-3-driven, tumor-stromal chemoresistance,[26] and in a gastric-cancer model MCP synergized with oxaliplatin to inhibit tumor growth — there by a galectin-3-independent route, raising the antioxidant enzyme SOD3 and modulating EGFR signaling, a reminder that not all of MCP's reported effects run through galectin-3.[25]
Chemotherapy-toxicity reduction — preclinical — MCP eased chemotherapy toxicity across three animal settings, each via galectin-3 inhibition: it alleviated oxaliplatin-induced peripheral neuropathy, a common dose-limiting toxicity, and enabled an oxaliplatin dose reduction without loss of efficacy in the gastric-cancer model;[25] reduced doxorubicin-induced cardiac injury in rats, with less oxidative stress and raised peroxiredoxin-4;[30] and attenuated cisplatin-induced kidney injury in mice, with less renal fibrosis and apoptosis.[31] The cardiac and renal studies used healthy, non-tumor-bearing animals, so they show organ protection rather than a whole-patient effect — and because galectin-3 inhibition shields normal tissue there, whether it could also protect a tumor from chemotherapy is a fair question. The tumor-bearing models above point the other way, with MCP enhancing, not blunting, chemotherapy's anti-tumor effect.
Scope — every finding here is preclinical and none is a human host-outcome, which is why the role is read as partial.
Prevent Arrest & Adhesion
Research concerning endothelial adhesion and platelet-mediated arrest at secondary sites.
Integrin–FAK–Src signaling (focal adhesion)
MCP's defining action: blocking the galectin-3-mediated adhesion tumor cells use to stick to blood-vessel walls and to each other, the step that lets a circulating cell arrest and seed a new site. Its most reproducible, most MCP-specific mechanism — shown in vivo, but at exposures oral dosing may not reach.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
By lowering galectin-3, MCP dampened Akt survival signaling and stalled the cell cycle, and oral MCP shrank a primary bladder tumor in animals — its clearest sign of acting on tumor growth rather than only on spread, still limited by the oral-exposure question.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
MCP's central pharmacokinetic fact is a question, not a number: whether an orally-taken polysaccharide is absorbed and reaches the tumor at all. The manufacturer-adjacent literature says yes; the one direct radiolabeled measurement says almost none; and a separate oral animal study shows a tumor effect anyway. The formulation matters too — only the modified, low-molecular-weight structure binds galectin-3, so ordinary pectin is not a substitute.
Absorption
Contested. The modified structure is said to allow uptake "into the circulation," but that is asserted, not measured in humans — and one radiolabeled animal study put oral bioavailability below 0.01%, with oral dosing ineffective while intravenous worked.
The Exposure Gap
In-vitro effects need hundreds of µg/mL to low mg/mL MCP — concentrations implausible in plasma after an oral polysaccharide dose. The human signal therefore rests on biomarker trials, not on reaching these levels at the tumor.
Clinical Dose Context
Oncology trials used large oral doses: the pilot used 15 g/day, and the prospective phase II program used PectaSol at 4.8 g three times daily for 6 to 18 months — achievable with retail powders and sachets.
Formulation Effects
The galectin-3 binding depends on the modified low-MW, low-esterification structure. Unmodified citrus pectin lacks the effect and in one melanoma model increased metastasis — so generic pectin is not interchangeable.
Metabolism
A soluble dietary-fiber polysaccharide, not expected to undergo liver (CYP) drug metabolism; unabsorbed material is likely fermented by gut bacteria. No active metabolite — and no human metabolism study — has been identified.
Co-Dosing Considerations
As a soluble fiber, MCP can slow the absorption of co-taken drugs and fat-soluble nutrients; human data show pectin lowers carotenoid uptake. Separating MCP in time from oral medications is prudent.
Absorption
This is the fact that governs how the entire profile above should be read. Native dietary pectin is a large (60–300 kDa), highly esterified polysaccharide that is neither digested nor absorbed. MCP is processed by controlled pH, heat, and enzymatic treatment to a low molecular weight (under 15 kDa) and a low degree of esterification (under 5%), which the manufacturer-adjacent literature states allows absorption from the small intestine into the circulation.[22] That claim is asserted rather than measured — no human plasma-level study exists — and it is directly challenged by the one quantitative measurement: a radiolabeled biodistribution study in tumor-bearing mice found oral MCP bioavailability below 0.01%, negligible tumor uptake, and no antitumor effect from oral dosing, while intravenous MCP produced roughly 50% tumor-growth reduction.[23] Against that, an oral bladder-xenograft study found oral MCP inhibited a primary tumor,[9] a genuine counterexample. The plausible reconciliation is that galectin-3 antagonism acts extracellularly, on circulating and matrix-bound lectin, so the compound may not need classic intracellular tissue uptake — but even an extracellular target still requires the polysaccharide, or an active fragment, to leave the gut and reach the circulation, which the direct measurement did not find. This resolves the conflict as a hypothesis, not a demonstrated systemic exposure.
The Concentration Gap
The concentrations that drive MCP's effects in cell culture are far above what an oral polysaccharide could plausibly reach in plasma. Migration inhibition, for instance, was produced at 0.25–1.0 mg/mL of PectaSol-C,[11] and apoptosis assays used concentrations near 1% by weight — orders of magnitude above any systemic level a swallowed dose would generate. This is why the human evidence base is biomarker trials rather than concentration-based reasoning: there is no route from these in-vitro doses to a measurable, effective plasma concentration in a person, and no human pharmacokinetic study has ever tried to establish one.
Clinical Dose Context
The doses used in the human prostate trials are large, reflecting a fiber-scale rather than a drug-scale product, and are achievable with standard retail formulations.
| Context | Dose | Source |
|---|---|---|
| Phase II pilot (biochemical failure) | 15 g/day | PSA doubling time increased in 7 of 10 evaluable men over 12 months[1] |
| Prospective phase II (6 months) | 4.8 g × 3/day (14.4 g/day) | PSA-doubling-time improvement in ~75%; significant median increase[2] |
| Long-term extension (to 18 months) | 4.8 g × 3/day | durable response 85%; doubling-time improvement 90%; imaging negative[3] |
Formulation Effects
Formulation is not a bioavailability lever here but a prerequisite for activity at all. The galectin-3 antagonism depends on the modified structure — the short-chain, low-esterification galactoside side chains that fit galectin-3's carbohydrate-recognition domain.[22] Unmodified citrus or food pectin does not share the effect, and in the B16 melanoma model it actually increased lung colonization while MCP suppressed it,[7] so ordinary pectin is not an interchangeable substitute. The human trial evidence is specific to the PectaSol and PectaSol-C preparations,[1,2,3] and product-to-product variation in molecular weight and esterification is the practical quality question a buyer faces.
Metabolism
MCP is a soluble dietary-fiber polysaccharide rather than a small-molecule drug, so it is not expected to undergo hepatic cytochrome-P450 metabolism, and no active metabolite has been identified; the unabsorbed fraction — which, given the absorption uncertainty above, may be most of the dose — is likely subject to colonic microbial fermentation like other soluble fibers.[24] No human MCP metabolism study was identified, and whether absorbed fragments or fermentation products contribute to its effects is unknown. Because its oncology rationale rests on direct target binding rather than on a metabolite, the absorption question, not a metabolism question, is the one that matters.
Co-Dosing Considerations
MCP's interaction profile is that of a soluble fiber, not a metabolic drug interaction. Each row is flagged by the most cautious guidance its cited evidence supports.
Discuss whether to combine, separate, or avoid Modified Citrus Pectin and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Monitor | Oral medications and fat-soluble nutrients taken at the same time — as a soluble fiber MCP can slow or reduce absorption; controlled human data show pectin lowered β-carotene absorption by roughly a third and other carotenoids more, without affecting vitamin E. This is general-pectin evidence, so the prudent step is timing separation from oral drugs rather than an assumed drug-specific effect.[27] |
Advertisement
04 — Onset & Washout
Onset and Washout
MCP's onset, half-life, and accumulation are uncharacterized. The human studies measured PSA kinetics over months — an interval set by how that biomarker is assessed, not evidence of how quickly or slowly MCP acts. What can be said about timing is mostly what is not yet known.
Immediate Onset
There is no measured plasma peak or fast physiological effect for oral MCP — appropriate for a large polysaccharide with an unresolved absorption profile. It should not be thought of as having an acute onset.
Steady State
No pharmacokinetic study has characterized accumulation or a steady-state level, so consistency of daily dosing — not any single dose — is what the trials relied on.
Accumulated Effect
The human studies tracked PSA doubling time over 6 to 18 months because that biomarker requires serial measurement over time. That is the observation window — not evidence that biological onset takes months, or that MCP accumulates.
Dosing Pattern in Studies
The trials used steady divided daily dosing over many months. This describes how MCP was studied, not a recommended regimen.
Washout
How long MCP's influence takes to clear before it stops being a relevant factor.
No compound-specific tissue-clearance or washout data were identified. Because MCP acts as a soluble fiber that can affect the absorption of other oral products, the relevant consideration begins as soon as use starts, not at a fixed clearance point — and any washout decision before a procedure or a new medication defers to the treating team.
Onset Is Uncharacterized
MCP's onset cannot be described from the available data. No pharmacological onset, plasma peak, or half-life has been measured in humans — appropriate for a large polysaccharide whose systemic absorption is itself unproven. The human studies observed changes in PSA doubling time over 6 to 18 months, but that reflects how the endpoint is measured — serial PSA values accrued over time — not a demonstration that biological onset takes months or that MCP must accumulate to act.[1,2,3] "Observed over months" and "takes months to begin acting" are different statements, and only the first is supported.
Steady State and Accumulation
No pharmacokinetic study has characterized steady-state levels or tissue accumulation for MCP, so there is no reservoir to describe — only the observation that the trials reporting a biomarker signal used uninterrupted daily dosing over long periods. Whether consistency of schedule, the size of any single dose, or neither is what drives an effect has not been established.
Dosing Pattern in Studies
The trials reporting a signal used steady divided daily dosing — commonly 4.8 grams three times a day — sustained across 6 to 18 months.[2,3] This describes how MCP was studied, not a recommended regimen.
Washout
No compound-specific tissue-accumulation or clearance washout window was identified for MCP this review. Its practical timing consideration is the reverse of a clearance window: because MCP behaves as a soluble fiber that can alter the absorption of co-taken oral drugs and nutrients, the relevant point is to raise absorption-timing with the care team as soon as use begins, rather than to manage a washout before a new medication — and any decision before a procedure defers to the treating team.
Advertisement
05 — Safety
Safety Profile
MCP is well tolerated in the human trials conducted so far, with an adverse-effect profile limited to the mild gastrointestinal effects expected of a large soluble-fiber dose.
Gastrointestinal bloating — the dominant adverse effect, transient and reversible: grade-1 bloating in about 20% of patients in the largest prostate trial, requiring no treatment discontinuation.
No high-grade toxicity — no grade 3 or 4 adverse events were reported across the prostate trials or the 18-month extension, and there were no toxicity-driven dropouts.
Soluble-fiber dose ceiling — expected fiber effects (bloating, gas, loose stools) are the likely practical limit on dose, though no formal dose-escalation study has defined a ceiling.
Rare pectin hypersensitivity — case reports describe allergic reactions to citrus-derived pectin, with possible cross-reactivity in cashew-allergic individuals; none was reported in the MCP oncology trials.
Adverse Effects in Human Trials
The human safety record is short but reassuring, and dominated by mild gastrointestinal effects consistent with a large soluble-fiber dose. In the 60-patient prostate phase II study, transient, reversible grade-1 bloating occurred in 20% (12 of 60 enrolled) and required no treatment discontinuation; there were no grade 3 or 4 toxicities, and the single early withdrawal was by consent rather than for an adverse event.[2] The 18-month long-term extension likewise reported no high-grade toxicity, with the few withdrawals again consent-related.[3] The earlier pilot study also found MCP tolerable across its treatment period.[1] In the larger advanced-solid-tumor pilot (49 patients, 15 g/day), the most common MCP-related effects were also mild — pruritus, dyspepsia, and flatulence — with no effect on vital signs or laboratory parameters, though one patient discontinued because of increasing pruritus.[29] Expected fiber effects — bloating, gas, and loose stools — are the likely practical limit on dose escalation rather than a sign of organ toxicity, though no formal dose-escalation study has defined a ceiling. Rather than a citrus allergy specifically, the documented concern is rare pectin hypersensitivity: case reports describe allergic reactions to citrus-derived pectin, including apparent cross-reactivity in cashew-allergic individuals, though no such reaction was reported in the MCP oncology trials.[28] Several settings remain uncharacterized — safety during concurrent chemotherapy has not been established in humans, and pregnancy, significant gastrointestinal disease, and renal or hepatic impairment are unstudied. MCP's one meaningful interaction consideration — its soluble-fiber effect on the absorption of co-taken oral drugs and nutrients — is set out under Co-Dosing Considerations in Pharmacokinetics and Administration above rather than repeated here.
06 — Sourcing
Sourcing Guide
Because only the modified low-molecular-weight, low-esterification structure binds galectin-3 — and ordinary citrus pectin does not — the specific preparation is what matters for MCP. Our Sourcing Guide offers a curated list of products available on the retail market.
Modified Citrus Pectin Sourcing Guide07 — Literature
References
Last reviewed: August 2026